3,5-diisopropylsalicylic acid has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harrich, D; Li, D; Li, L; Lin, MH; Suhrbier, A; Tang, B | 1 |
| Fu, X; Jiang, C; Li, J; Sheng, R; Su, W; Wu, M; Zhou, E | 1 |
| Baedeker, M; Möller, CC; Ringel, MS; Schulze, U | 1 |
1 review(s) available for 3,5-diisopropylsalicylic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Defective Interfering Particles of Influenza Virus and Their Characteristics, Impacts, and Use in Vaccines and Antiviral Strategies: A Systematic Review.
Topics: Antiviral Agents; COVID-19; Defective Interfering Viruses; Defective Viruses; Humans; Influenza Vaccines; Orthomyxoviridae; SARS-CoV-2; Virus Replication | 2022 |
2 other study(ies) available for 3,5-diisopropylsalicylic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Defective Interfering Particles with Broad-Acting Antiviral Activity for Dengue, Zika, Yellow Fever, Respiratory Syncytial and SARS-CoV-2 Virus Infection.
Topics: Animals; Antiviral Agents; COVID-19; Defective Interfering Viruses; Dengue; Dengue Virus; Humans; Interferon Type I; SARS-CoV-2; Yellow Fever; Yellow fever virus; Zika Virus; Zika Virus Infection | 2022 |
2022 FDA approval number dips: a COVID-19 hangover?
Topics: Alcoholic Intoxication; COVID-19; Humans | 2023 |